STONY BROOK, NY--(Marketwired - June 06, 2016) - Applied DNA Sciences (ADNAS), Inc. (NASDAQ: APDN), a provider of DNA-based supply chain, anti-counterfeiting, genotyping and anti-theft technology, and authentication technologies, announced today the appointment of Dr. Barbara Brockway as Director of Personal Care.

Dr. Brockway is an innovator and leader in the world of cosmetics formulation, food science, branding, and supply chain management in the personal care industry.

Dr. Brockway is a sought after speaker in personal care, lecturing on topics such as biochemistry, rheology, cereal science, food science, and the latest technology in cosmetics. A well-respected author of published scientific papers and chapters in technical books and trade journals, Dr. Brockway is often called upon by companies and organizations for collaborative projects on reimagining the future of personal care as consumers become more conscious about sustainability and proof of origin.

Dr. Brockway's experience includes being Scientific Advisor at IMCD, Laboratory Manager at Huntsman LLC, Director of R&D/Marketing at The Collaborative Group, Ltd, and Head of Applied Research at The Body Shop International.

While at The Body Shop, Dr. Brockway was recognized with the "Walk the Talk" award for being a passionate advocate of the company's ethics and culture.

Dr. Brockway also holds or held a number of high-level positions in the personal care industry including being the Past President of the Society of Cosmetic Scientists, a Trustee on The Body Shop Foundation and a Governor of Chichester University.

Dr. Brockway holds a Ph.D. in Biochemistry and a B.Sc. with honors from the University of Kent.

"We are delighted to have Dr. Brockway join Applied DNA Sciences at a time where there is significant need for consumers to better understand the origin of the personal care products they buy. Through the development of partnerships with personal care companies, Dr. Brockway is poised to bring greater confidence to consumers and companies alike," said Dr. James Hayward, CEO and president of Applied DNA Sciences, Inc. He continued: "The integration of personal care complements our expansion into pharmaceutics, markets that are regulated by the FDA, in which authenticity and supply chain transparency are essential."

About Applied DNA Sciences

We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Our patented DNA-based solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature® DNA describes the platform ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. We are also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements

The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 10, 2016 and May 12, 2016 which are available at APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contact Information:

Investor contact:
Debbie Bailey

Media contact:
Susan Forman
Dian Griesel Int'l.

twitter: @APDN